Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...

The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.

MRNA is showing early signs of a new bull trend after earnings beat expectations, with technical support holding and upside targets forming above key resistance levels.

Dow Jones Top Company Headlines at 5 PM ET: Anthropic Adds New Board Member as It Eyes IPO | Moderna ... The former Microsoft and GM executive Chris Liddell has previously worked for the Trump ...

Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.

Applied Materials shares surged after the semiconductor-equipment maker beat analysts’ quarterly earnings estimates.

Odds of a Fed rate cut in June nudge higher after 'core' consumer inflation comes in at its lowest rate in four years.

Moderna (NASDAQ:MRNA) is escalating its standoff with US regulators at a delicate juncture in its post-pandemic reset. On Friday's analyst call, Chief Executive Officer Stephane Bancel described the ...

In a rare and surprising move, the FDA has issued a “Refusal to File” letter for Moderna’s mRNA-1010 influenza vaccine.

After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient ...

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.